Core Viewpoint - The recent announcements from multiple listed companies regarding regulatory actions highlight the regulatory authorities' zero-tolerance stance towards information disclosure violations, which is expected to enhance investor trust and confidence in the market [1]. Group 1: Regulatory Actions - Several companies received notices from regulatory bodies for suspected violations of information disclosure laws, indicating a crackdown on such practices [1]. - Ju Shi Chemical announced it received a "Notice of Investigation" from the CSRC due to suspected information disclosure violations, stating that its business operations remain normal during the investigation [2]. - Haoer Sai also received a "Notice of Investigation" from the CSRC for similar reasons, affirming that its operations are not significantly impacted by the investigation [2]. Group 2: Administrative Penalties - Jia Ying Pharmaceutical received an administrative penalty decision from the Guangdong Securities Regulatory Bureau, which included a warning and a fine of 1.5 million yuan for failing to disclose related party transactions properly, involving a total of 21.999 million yuan, which constituted 28.83% of its latest audited net assets [3]. - Hengli Industrial, which was delisted in July, received a notice of administrative penalty from the Hunan Securities Regulatory Bureau, proposing a fine of 8 million yuan for false records in its annual reports from 2020 to 2022 [4]. Group 3: Specific Cases of Violations - Zhihua Power's actual controllers and a former executive received a notice of administrative penalty for failing to disclose significant agreements related to share transfers, which involved 5.1% of the company's total shares, amounting to 208.61 million yuan [6][7]. - The Shenzhen Securities Regulatory Bureau proposed a fine of 1.5 million yuan against the actual controllers of Zhihua Power for their failure to disclose the signing of supplementary agreements that significantly impacted the company [8]. - A former vice president of Zhihua Power, Chen Danhua, faced a warning and a proposed fine of 800,000 yuan for violating company law by exceeding the limit on share transfers during a restricted period [9].

天眼查资料显示，嘉应制药成立于2003年03月07日，注册资本50750.9848万人民币，法定代表人李能，注册地址为广东省梅州市东升工业园B区。主营业务 为中成药的研发、生产和销售。 雷达财经 文|杨洋 编|李亦辉 11月21日，广东嘉应制药股份有限公司（证券简称：嘉应制药，证券代码：002198）公告，公司因存在关联方非经营性资金往来未依法履行关联交易审议程 序及未及时披露的行为，涉及金额21,999万元，占公司最近一期经审计净资产的28.83%，被中国证监会广东监管局处以警告及罚款。 其中，公司被罚款150万元，董事长李能被罚160万元，总经理游永平被罚100万元，时任财务总监史俊平被罚80万元。 公司表示此次处罚不触及重大违法强制退市情形，生产经营正常，并向投资者致歉。 目前，公司董事长为李能，董秘为孙俊，员工人数为594人。 公司参股公司6家，包括广东嘉惠融资租赁有限公司、湖南金沙药业有限责任公司、广东嘉应医药有限公司、嘉应（深圳）大健康发展有限公司、广东康慈 医疗管理有限公司等。 在业绩方面，公司2022年、2023年、2024年和2025年前三季度营业收入分别为6.59亿元、5.33亿元、3.7 ...

Core Points - Jia Ying Pharmaceutical received an administrative penalty from the China Securities Regulatory Commission for illegal information disclosure and related party transactions [1][2][3] - The company and its chairman, Li Neng, were involved in short-term fund lending to a related party, Yao Juneng, without proper disclosure and approval [1][2] - The company reported a significant decline in revenue and net profit over the past two years, with 2024 revenue dropping by 29.46% year-on-year [3][4] Group 1: Regulatory Actions - Jia Ying Pharmaceutical was fined 1.5 million yuan, while Li Neng was fined 1.6 million yuan, totaling 4.9 million yuan in penalties for the violations [2] - The Guangdong Securities Regulatory Bureau issued a warning letter to the company for failing to disclose financial assistance and related party transactions [2][3] - The company acknowledged the violations and committed to enhancing compliance awareness [2] Group 2: Financial Performance - In 2024, Jia Ying Pharmaceutical's revenue was 37.6 million yuan, a decrease of 29.46% year-on-year, and the net profit dropped by 39.94% to 20.61 million yuan [3] - The company's gross margin fell from 75.31% in 2021 to 59.93% in 2024, indicating a declining profitability trend [3] - For the first three quarters of 2025, the company reported a revenue of 29.3 million yuan, a year-on-year increase of 13.0%, and a net profit of 21.79 million yuan, a significant increase of 658.5% [3][4]

Group 1 - The core issue involves regulatory actions taken against Jiaying Pharmaceutical for failing to disclose related party transactions properly, which amounted to approximately 8.7558 million yuan, representing 1.15% of the company's latest audited net assets [1] - The company and its executives, including the chairman and general manager, were found to have violated multiple provisions of the stock listing rules, indicating a lack of diligence and responsibility in their roles [1] - The company is urged to learn from this incident and ensure compliance with relevant laws and regulations, including the Securities Law and Company Law, to prevent future occurrences [1] Group 2 - For the first half of 2025, Jiaying Pharmaceutical's revenue composition was heavily weighted towards the pharmaceutical industry, accounting for 99.96%, with other businesses making up only 0.04% [2] - As of the report date, Jiaying Pharmaceutical's market capitalization was 3.4 billion yuan [2]

证券代码：002198 证券简称：嘉应制药 公告编号：2025-063 广东嘉应制药股份有限公司 一、警示函主要内容 广东嘉应制药股份有限公司、李能、游永平、史俊平、肖巧霞： 经查，广东嘉应制药股份有限公司（以下简称嘉应制药或公司）存在以下信 息披露违规行为： 一、未按规定披露对外财务资助情况。2024年9月至2024年11月，嘉应制药 子公司嘉应制药（湖南）有限公司向三家非关联企业提供合计6500万元财务资助， 上述财务资助未按规定履行相关审议程序和披露义务，不符合《深圳证券交易所 上市公司自律监管指引第1号——主板上市公司规范运作（2023年12月修订）》第 6.1.3条第一款的规定，违反了《上市公司信息披露管理办法》（证监会令第182 号，下同）第三条第一款的规定。 二、未按规定披露公司日常关联交易情况。2024年，嘉应制药总经理游永平 弟媳刘某民为广东共合医药有限公司（以下简称共合医药）的控股股东，根据《上 市公司信息披露管理办法》第六十二条第四项的规定，共合医药构成嘉应制药的 关联方。2024年9月至2024年12月，嘉应制药与共合医药开展中成药交易，相关 关联交易涉及金额约875.58万元，占公司 ...

证券代码：002198 证券简称：嘉应制药 公告编号：2025-062 广东嘉应制药股份有限公司 关于公司及相关责任人收到《行政处罚决定书》的公告 本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日收到 中国证券监督管理委员会下发的《立案告知书》（编号：证监立案字 0062025010 号）。因公司涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民 共和国行政处罚法》等法律法规，中国证券监督管理委员会决定对公司立案。具 体内容详见公司于 2024 年 5 月 29 日披露在《证券时报》《中国证券报》《证券日 报》和巨潮资讯网（http://www.cninfo.com.cn）的《关于收到中国证券监督管理 委员会立案告知书的公告》（公告编号：2025-033）。 2025 年 8 月 1 日，公司及相关责任人收到中国证券监督管理委员会广东监 管局下发的《行政处罚事先告知书》（广东证监处罚字[2025]10 号），具体内容详 见公司于 2025 年 8 月 4 日在上述媒体披露的《关于 ...

格隆汇11月21日｜嘉应制药公告，因公司涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中 华人民 共和国行政处罚法》等法律法规，中国证券监督管理委员会决定对公司立案。 ...

嘉应制药公告，公司及相关人员于 2025年 11月 21日收到广东证监局出具的警示函。经查，嘉应制药存 在信息披露违规行为，包括未按规定披露对外财务资助情况和未按规定披露公司日常关联交易情况。 2024年 9月至 2024年 11月，嘉应制药子公司嘉应制药（湖南）有限公司向三家非关联企业提供合计 6500万元财务资助，未按规定履行相关审议程序和披露义务。2024年 9月至 2024年 12月，嘉应制药与 共合医药开展中成药交易，相关关联交易涉及金额约 875.58万元，占公司最近一期经审计净资产的 1.15%，上述关联交易未按规定履行相关审议程序和披露义务。 ...

嘉应制药公告，公司及相关责任人收到中国证券监督管理委员会广东监管局下发的《行政处罚决定 书》。因公司信息披露违法违规，被处以警告并罚款150万元；董事长李能罚款160万元；总经理游永平 罚款100万元；时任财务总监史俊平罚款80万元。公司表示，该处罚不会对公司生产经营产生重大影 响。 ...

Group 1: New Stock Offerings - Tianpu Co., Ltd. (Stock Code: 605255) has a tender offer period from November 20, 2025, to December 19, 2025[1] - Hangzhou Steam Turbine Co., Ltd. (Stock Code: 200771) has a cash option declaration period from November 19, 2025, to November 25, 2025[1] - Central Plaza (Stock Code: 600280) announced on November 20, 2025[1] Group 2: Stock Performance Alerts - Moen Electric (Stock Code: 002451) reported severe abnormal fluctuations on November 14, 2025[1] - ST Yuancheng (Stock Code: 603388) reported severe abnormal fluctuations on November 11, 2025[1] - ST Keli Da (Stock Code: 603828) reported severe abnormal fluctuations on November 12, 2025[1] Group 3: Recent Announcements - Jiumuwang (Stock Code: 601566) announced on November 20, 2025[1] - Taiping Bird (Stock Code: 603877) announced on November 20, 2025[1] - Huaci Co., Ltd. (Stock Code: 001216) announced on November 20, 2025[1]